Guidance for the Discontinuation or Switching of Antidepressant Therapies in Adults
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Antidepressants (ADs) are commonly used for the treatment of various psychological and other medical disorders. Patient response and regimen duration with individual agents varies, necessitating discontinuation (DC) and/or switching between ADs. However, withdrawal symptoms may occur upon DC of the AD, and clinical symptom control may be compromised if the change to a new AD agent is not initiated appropriately. The purpose of this evaluation was to review the available literature and resources to compile documented methods for discontinuing or changing AD regimens in the clinical setting into a single guidance document. The results of this evaluation have yielded both detailed and general recommendations for practitioners to use and consider in discontinuing an AD and making changes between AD agents. The information provided herein is intended to provide useful guidance for clinicians and other health care professionals in their management of patients discontinuing or switching between selected AD agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1997) · PubMed · Cited by 149
Antidepressant discontinuation: a review of the literature.
Lejoyeux, M., & Adès, J. (1997) · PubMed · Cited by 148
Sir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1015 · Cited by 129
Newer antidepressants and the discontinuation syndrome.
Haddad, P. M. (1997) · PubMed · Cited by 101
Baldwin, D. S., Cooper, J. A., Huusom, A. K. T., & Hindmarch, I. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194377.88330.1d · Cited by 100 · cited 2×
“Overall, studies have not determined which method of taper is best.(1,2,4) Patients should be educated on the risks and symptoms associated with AD withdrawal, as this is a key factor in management.”
MethodResultClinical management of antidepressant discontinuation.
Rosenbaum, J. F., & Zajecka, J. (1997) · PubMed · Cited by 99
Perahia, D. G. S., Quail, D., Desaiah, D., Corruble, E., & Fava, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0113 · Cited by 46
Steps Following Attainment of Remission: Discontinuation of Antidepressant
Shelton, R. C. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0404 · Cited by 43
Extended antidepressant maintenance and discontinuation syndromes
Maixner, S. M., & Greden, J. F. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)8:1+<43::aid-da7>3.0.co;2-c · Cited by 22
Tapering antidepressants: is 3 months slow enough?
Phelps, J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.08.035 · Cited by 16
Research works printed but not linked: 6
- 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
- Schatzberg AF, 1997, J Clin Psychiatry, 58, 5
- Haddad P, 1997, J Clin Psychiatry, 58, 17
- Lejoyeux M, 1997, J Clin Psychiatry, 58, 11
- Rosenbaum JF, 1997, J Clin Psychiatry, 58, 37
- Cohen LJ, 2009, Primary Psychiatry, 16, 1
Cited by
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
“Tapering schedules Most articles reviewed agree that tapering is unnecessary for patients who have been taking an antidepressant for 4 weeks or less as this is insufficient time to develop a withdrawal reaction [Ogle and Akkerman, 2013; Haddad and Anderson, 2007; Edwards, 2006].”
BackgroundResultInfluentialKudlow, P., McIntyre, R., & Lam, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0171-5 · Cited by 84
Antidepressant discontinuation syndrome
Gabriel, M., & Sharma, V. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.160991 · Cited by 98
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Anticholinergic burden: considerations for older adults
O’Donnell, L. K., Gnjidic, D., Nahas, R., Bell, J. S., & Hilmer, S. N. (2016) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1303 · Cited by 78
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
O’Connell, C. P., Goldstein‐Piekarski, A. N., Nemeroff, C. B., Schatzberg, A. F., DeBattista, C., Carrillo‐Roa, T., Binder, E. B., Dunlop, B. W., Craighead, W. E., Mayberg, H. S., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17020172 · Cited by 53
Zhou, Q., Li, X., Yang, D., Xiong, C., & Xiong, Z. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114431 · Cited by 47
“Serotonin can influence various neurological functions such as mood, cognition, sleep, pain, motor activity, and autonomic regulation [52].”
The art and science of drug titration
Caffrey, A. R., & Borrelli, E. P. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620958910 · Cited by 43
Management of Chronic Pain in Nursing Homes: Navigating Challenges to Improve Person-Centered Care
Sheikh, F., Brandt, N., Vinh, D., & Elon, R. D. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.12.029 · Cited by 32
Cohen, D., & Recalt, A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496733 · Cited by 28
Givens, C. (2016) · Nursing Clinics of North America · doi:10.1016/j.cnur.2016.01.013 · Cited by 29
Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom, R. P., Alexander, J. L., Baron, D. A., Garakani, A., Gross, L. S., Pine, J. H., Radhakrishnan, R., Slaby, A. E., & Sumner, C. R. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000578 · Cited by 21
Hudd, T. R., Blake, C. S., Rimola-Dejesus, Y., Nguyen, T.-T., & Zaiken, K. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019841742 · Cited by 20
Papoutsaki, A., So, S., Kenderova, G., Shapiro, B. B., & Epstein, D. A. (2021) · Proceedings of the ACM on Human-Computer Interaction · doi:10.1145/3479564 · Cited by 21
“Package inserts from drug manufacturers are similarly vague, indicating that abrupt discontinuation is not recommended and that tapering should be monitored for withdrawal symptoms [76].”
BackgroundJo, E., Ryu, M., Kenderova, G., So, S., Shapiro, B. B., Papoutsaki, A., & Epstein, D. A. (2022) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3491102.3502206 · Cited by 22
Sonoyama, T., Shimizu, R., Kubota, R., Matsuo, Y., Okutsu, D., Yamanaka, H., Takasu, K., Ogawa, K., & Motomiya, T. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12359 · Cited by 13
Wallis, K. A., Donald, M., Horowitz, M. A., Moncrieff, J., Ware, R. S., Byrnes, J., Thrift, K., Cleetus, M., Panahi, I., Zwar, N. A., et al. (2023) · Trials · doi:10.1186/s13063-023-07646-w · Cited by 18
“Patients report being advised to wean off antidepressants over about 4 weeks by halving their dose and then halving again [23, 33].”
BackgroundSenese, N. B., & Rasenick, M. M. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.120.000226 · Cited by 10
Antidepressant Discontinuation: In Need of Scientific Evidence
Vinkers, C. H., Ruhé, H. G., & Penninx, B. W. J. H. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001460 · Cited by 11
Chen, X.-L., Li, X., Gan, Y., Lu, Y. C., Tian, Y., Fu, Y., Yang, H., Liu, K., Pan, Y., & Du, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1031616 · Cited by 9
Jo, E., Zehrung, R., Genuario, K. E., Papoutsaki, A., & Epstein, D. A. (2024) · Proceedings of the ACM on Human-Computer Interaction · doi:10.1145/3686997 · Cited by 14
“However, there is no established protocol for planning the gradual discontinuation of antidepressants [52, 76].”
BackgroundSecondary organizing pneumonia associated with sertraline: A case report
Trungu, J., Pirard, L., Vandenhove, T., Pop, C. S., Dahlqvist, C., & Sohy, C. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101141 · Cited by 7
“It was then decided to gradually taper off the sertraline, initially at half dose over two weeks before complete withdrawal [7,8].”
BackgroundGallart‐Palau, X., Muntané, G., Martorell, L., Amigó, N., Correig, X., Ribalta, J., Sánchez‐Gistau, V., Labad, J., & Vilella, E. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00847 · Cited by 6
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Maji, S., Mishra, A., Mohapatra, D., Mishra, B. R., Jena, M., Srinivasan, A., & Maiti, R. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116257 · Cited by 5
Winger, B. A., Long, S. E., Brooks, J. C., Gupta, A. O., Dvorak, C. C., & Long-Boyle, J. R. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.713091 · Cited by 5
Ran, M., Zhang, H., Jin, M., Tao, Y., Xu, H., Zou, S., Wang, Z., Deng, F., Huang, L., Zhang, H., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1487754 · Cited by 5
A risk identification model for detection of patients at risk of antidepressant discontinuation
Zolnour, A., Eldredge, C. E., Faiola, A. J., Yaghoobzadeh, Y., Khani, M., Foy, D., Topaz, M., Kharrazi, H. H. K., Fung, K. W., Fontelo, P. A., et al. (2023) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2023.1229609 · Cited by 5
“However, medications used to treat depression may require weeks to achieve an adequate response and patients’ varied responses to depression treatment often require medication adjustment (Ogle and Akkerman, 2013).”
BackgroundDelirium Associated With Fluoxetine Discontinuation: A Case Report
Fan, K.-Y., & Liu, H. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000214 · Cited by 4
“However, some authors suggest a gradual tapering of fluoxetine over a minimum of 2 weeks if the dosage is more than 40 mg/d.(6) Delirium associated with fluoxetine discontinuation has been reported in the literature only twice.”
BackgroundOptimal Time Allocation between Idle and Active Time
Weber, M., Gonen, L. D., Westreich, S., & Spiegel, U. (2017) · Applied Economics and Finance · doi:10.11114/aef.v4i4.2506 · Cited by 2
“In addition, when antidepressants are discontinued an antidepressant withdrawal syndrome must be avoided (Hirsch & Birnbaum, 2012; Ogle & Akkerman, 2013).”
BackgroundBoland, M., Higgins, A., Beecher, C., Bracken, P. J., Burn, W., Cody, A., Framer, A., Gronlund, T. A., Horowitz, M. A., Huff, C., et al. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13649.1 · Cited by 2
Treatment for Anxiety Disorders in the Pediatric Primary Care Setting
Blossom, J. B., Jungbluth, N. J., Dillon-Naftolin, E., & French, W. P. (2023) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2023.02.003 · Cited by 4
Mobile phone applications to support psychotropic tapering: a scoping review protocol
Boland, M., Higgins, A., Doherty, G. J., Sheaf, G., Framer, A., & Cadogan, C. A. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13501.2 · Cited by 2
“A similar approach involves switching to an alternative medication with a longer half-life before beginning gradual dosage reduction 16,25 .”
InfluentialYang, J., Jia, Y., Chen, K., Liang, W., Long, J., Li, M., Wei, Q., Wang, J., Yan, B., Li, K., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1740789 · Cited by 1
“Although minimal improvement by 2 weeks may predict ultimate failure (10), clinical guidelines and comprehensive consensus recommend waiting at least 4 weeks to evaluate response (11 – 13).”
Strategies and Solutions for Switching Antidepressant Medications
Soreide, K. K., Ward, K. M., PharmD, Bostwick, J. R., Bcps, & Bcpp (2017) · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Stopping antidepressants: Clinical considerations
Tanzi, M. G. (2016) · Pharmacy Today · doi:10.1016/j.ptdy.2016.04.029
Galland, D., & Taillefer, B. (2016) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2016.08.009
Istrate, B. M., & Vîlciu, C. (2020) · Psihiatru ro · doi:10.26416/psih.61.2.2020.3586
Feßler, J., Fräulin, A., Niebling, W.-B., Streitlein-Böhme, I., Schröder, F., Seffrin, J., Unteregger, E., & Waschkies, M. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-21521-6.00008-3
Using SNRIs to prevent migraines in patients with depression
Ismail, H. H. (2022) · Current Psychiatry · doi:10.12788/cp.0290
Rizal, R. R., & Fiana, D. N. (2019) · Medical Profession Journal of Lampung · doi:10.53089/medula.v11i2.186
Geriatric Pharmacotherapy Case Series: Evaluating Fall Risk in Older Adults with Hyponatremia
Gurvich, T., Paxos, C., & Sánchez, N. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.390
Metadata
- Authors
- Ogle, N. R., & Akkerman, S. R.
- Affiliations
- The University of Kansas Health System (US)
- Nebraska Medical Center (US)
- Corresponding author
- Ogle, Nikki R.
- Venue
- Journal of Pharmacy Practice
- Publisher
- SAGE Publications
- Published
- 2013-03-04
- Volume
- 26
- Issue
- 4
- Pages
- 389-396
- ISSN
- 0897-1900 (ISSN-L)
- 1531-1937
- OpenAlex
- W2114293474
- Cited by
- 45
- References
- 11
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 4 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 4 · 2015: 1 · 2014: 1
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Pharmacy Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- antidepressants, antidepressant discontinuation, antidepressant switching, antidepressant withdrawal symptoms, depression treatment, clinical guidelines, medication regimen changes
- MeSH terms
- Adult, Antidepressive Agents, Humans, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.